Vera Therapeutics

VERA

Market cap $3.44B

The consensus price target hints at a 53.1% upside potential for Vera Therapeutics (VERA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Vera Therapeutics, Inc. (VERA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

BRISBANE, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on January 5, 2026, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 228,750 shares of Class A common stock and restricted stock units (RSUs) underlying 116,000 shares of Class A common stock to eighteen (18) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).

The biotech has formally submitted a biologics license application to the FDA for its kidney disease drug. It has been accepted for priority review by the healthcare industry regulator.

Vera Therapeutics Inc. (NASDAQ: VERA) stock rose Wednesday after the U.S. Food and Drug Administration (FDA) accepted the company's atacicept Biologics License Application (BLA) for Priority Review.

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Wells Fargo analysts believe a combination of tax refund spending, stronger earnings in lagging sectors, and fresh liquidity from the Federal Reserve could spark a “reflation” in equities. In a note led by strategist Ohsung Kwon, the investment firm said heavily shorted names in the “Russell 3000” may be particularly well-positioned for a rebound.

BRISBANE, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 6,138,108 shares of its Class A common stock at a price to the public of $42.50 per share.

BRISBANE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera Therapeutics”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock.

BRISBANE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on December 2, 2025, the Compensation Committee of the Board of Directors of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 42,000 shares of Class A common stock and restricted stock units (RSUs) underlying 21,000 shares of Class A common stock to seven (7) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan).